Japan-based Hisamitsu Pharmaceutical has launched the Salonpas® Diclofenac Patch 1% in Singapore. It is the first in the Salonpas® line to use diclofenac, a clinically-used ingredient that is powerful and efficacious and penetrates to alleviate pain at its core.

Singapore is the first market in South East Asia outside of Japan to get the new product, in line with Hisamitsu’s recognition of the ageing yet active population in Singapore.

Each patch measures 7cm by 10cm and contains 15mg of diclofenac sodium. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve severe, persistent pain and relieve symptoms such as inflammation, swelling, stiffness and joint pain. The powerful and efficacious ingredient of the patch penetrates deeply into the body to alleviate pain at its core.

“The everyday comfort and health of our consumers is Hisamitsu’s topmost priority. By launching the Salonpas® Diclofenac Patch 1% in Singapore, we aim to help customers of different age groups and lifestyles, from senior citizens to sports enthusiasts to working professionals achieve higher quality of life,” said Katsuhiro Sato, Executive Officer, General Manager APEA Sales Headquarters, International Division of Hisamitsu.